Skip to main content
Isofol Medical logo

Isofol Medical — Investor Relations & Filings

Ticker · ISOFOL ISIN · SE0009581051 LEI · 549300MCXYAHG7VBHX75 ST Professional, scientific and technical activities
Open in API
Filings indexed 208 across all filing types
Latest filing 2026-03-18 Regulatory Filings
Country SE Sweden
Listing ST ISOFOL

About Isofol Medical

https://isofolmedical.com/

Isofol Medical is a clinical-stage biotechnology company dedicated to improving treatments for severe forms of cancer. The company's primary focus is the development of its lead drug candidate, arfolitixorin. This next-generation, folate-based therapy is designed to enhance the efficacy of standard cancer treatments, such as chemotherapy. Arfolitixorin is the active metabolite of commonly used folate-based drugs, potentially offering a therapeutic benefit to a broader patient population by bypassing complex metabolic activation steps. The company's goal is to help more patients respond better to their treatment, thereby improving their prognosis.

Recent filings

Filing Released Lang Actions
Isofol secures license rights for arfolitixorin in autism
Regulatory Filings Classification · 95% confidence The document is a press release from Isofol Medical AB announcing the expansion of a license agreement for their drug candidate, arfolitixorin, to include autism spectrum disorder. This is a corporate announcement regarding business development and strategic expansion, which does not fit into specific financial reporting categories like 10-K, IR, or ER. As it is a general regulatory announcement regarding company operations, it falls under the RNS (Regulatory Filings) category.
2026-03-18 English
Teckningskursen för teckningsoptioner av serie TO1 i Isofol har fastställts till 0,48 SEK och nyttjandeperioden inleds den 16 mars 2026
Share Issue/Capital Change Classification · 95% confidence The document is a press release from Isofol Medical AB announcing the subscription price and exercise period for warrants (series TO1). It details the terms of the warrant exercise, the dilution effect, and the process for shareholders to exercise their rights. This falls under the category of capital structure changes and share issuance/subscription updates, which is best classified as 'Share Issue/Capital Change' (SHA).
2026-03-13 Swedish
The subscription price for warrants of series TO1 in Isofol has been set at SEK 0.48 and the exercise period commences on 16 March 2026
Share Issue/Capital Change Classification · 95% confidence The document is a press release from Isofol Medical AB regarding the exercise period, subscription price, and terms for warrants of series TO1. It details the mechanics of the warrant exercise, including the exercise price (SEK 0.48), the exercise period (16 March 2026 – 30 March 2026), and information on guarantee commitments. This falls under the category of capital and financing updates as it relates to the company's capital structure and the exercise of financial instruments.
2026-03-13 English
Isofol erhåller toppgarantiåtagande och avsiktsförklaringar motsvarande 42 procent av kommande optionsinlösen
Capital/Financing Update Classification · 95% confidence The document is a press release from Isofol Medical AB regarding a 'top guarantee commitment' and 'letters of intent' from shareholders concerning the exercise of TO1 warrants. It details the financial mechanics of the warrant exercise, the involvement of underwriters, and the timeline for the exercise period. This falls under the category of capital structure changes and financing updates, specifically related to warrant exercise and underwriting commitments.
2026-03-11 Swedish
Isofol receives top guarantee commitment and letters of intent corresponding to 42 percent of upcoming warrant exercise
Capital/Financing Update Classification · 95% confidence The document is a press release from Isofol Medical AB regarding a 'top guarantee commitment' and 'letters of intent' related to the exercise of series TO1 warrants. It details the financial mechanics of the warrant exercise, the involvement of a guarantor (Solasia Pharma K.K.), and the role of advisors. While it discusses capital-related activities, it is specifically an announcement regarding the status and commitments surrounding a capital instrument (warrants) rather than a formal prospectus or a financial report. Under the provided definitions, this fits best as a 'Capital/Financing Update' (CAP) as it provides an update on the company's financing activities and capital structure changes.
2026-03-11 English
Isofols valberedning föreslår nyval av Christian Haglund
Board/Management Information Classification · 98% confidence The document is a press release announcing the nomination of a new board member (Christian Haglund) by the nomination committee of Isofol Medical AB ahead of their upcoming Annual General Meeting. This falls under the category of board and management changes/information.
2026-03-09 Swedish

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.